FIELD: medicine.
SUBSTANCE: invention relates to a compound of formula (IB'), a tautomer or a pharmaceutically acceptable salt thereof, as well as a based pharmaceutical composition and a method of treating using it 
(IB').
EFFECT: what is presented is a novel compound, a composition and a method effective for treating a disease associated with overexpression of cyclin-dependent kinase (CDK) in mammals.
32 cl, 10 ex, 14 tbl, 15 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINATION THERAPIES FOR THE TREATMENT OF CANCER | 2016 |
|
RU2759963C2 |
| METHODS OF INFLUENCING TRANSCRIPTION CONTROL IN SUPER-ENHANCER AREAS | 2015 |
|
RU2737508C2 |
| COMBINATION THERAPY FOR HEPATOCELLULAR CARCINOMA | 2017 |
|
RU2769251C2 |
| COMBINATIONS OF INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE AND CHEMIOTHERAPEUTIC AGENTS AND METHODS OF APPLICATION | 2008 |
|
RU2523890C2 |
| OXAZOLIDINE-CONTAINING DIMER COMPOUNDS, COMPOSITIONS AND METHODS OF THEIR OBTAINING AND APPLICATION | 2010 |
|
RU2557910C2 |
| SALTS OF ISOPHOSPHORAMIDE YPRITE AND ITS ANALOGUES | 2008 |
|
RU2527531C2 |
| ANTAGONISTS OF TOL-LIKE RECEPTOR 4 AND USE IN AUTOIMMUNE LIVER DISEASES | 2016 |
|
RU2707560C2 |
| 2-CARBOXAMIDE CYCLOAMINO UREA DERIVATIVES IN COMBINATION WITH HSP90 INHIBITORS FOR TREATING PROLIFERATIVE DISEASES | 2012 |
|
RU2624493C2 |
| COMBINATIONS OF ANTIFOLATE AGENT IN CANCER TREATMENT | 2007 |
|
RU2423114C2 |
| COMBINATION OF PROTEIN KINASE INHIBITOR AND ADDITIONAL CHEMOTHERAPEUTIC AGENT | 2017 |
|
RU2785997C1 |
